Sterling Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Sterling Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-345,406	Closed	-$1.01M	–	930
2018 Q1	$1.01M	Hold	345,406	–	–	0.01%	609
2017 Q4	$946K	Hold	345,406	–	–	0.01%	648
2017 Q3	$1.17M	Hold	345,406	–	–	0.01%	559
2017 Q2	$853K	Buy	+345,406	New	+$794K	0.01%	663
2017 Q1	–	Sell	-204,916	Closed	-$434K	–	1060
2016 Q4	$434K	Hold	204,916	–	–	﹤0.01%	794
2016 Q3	$686K	Buy	+204,916	New	+$650K	0.01%	647
2015 Q3	–	Sell	-64,414	Closed	-$414K	–	1103
2015 Q2	$414K	Sell	64,414 -977	-1%	-$6.54K	﹤0.01%	751
2015 Q1	$460K	Sell	65,391 -143,510	-69%	-$1.04M	﹤0.01%	717
2014 Q4	$1.61M	Sell	208,901 -2,451	-1%	-$19.4K	0.01%	490
2014 Q3	$1.58M	Buy	+211,352	New	+$1.96M	0.02%	462
2014 Q2	–	Sell	-159,473	Closed	-$1.32M	–	1004
2014 Q1	$1.32M	Buy	159,473 +122,675	+333%	+$1.05M	0.01%	490
2013 Q4	$311K	Buy	+36,798	New	+$310K	﹤0.01%	717
2013 Q3	–	Sell	-40,986	Closed	-$316K	–	756
2013 Q2	$316K	Buy	+40,986	New	+$320K	﹤0.01%	474

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Sterling Capital Management's PDLI Position: Q2 2018 in Review

Sterling Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q2 2018, closing a stake of 345,406 shares — an estimated $1.01M sold.

Sterling Capital Management first reported a position in PDLI in Q2 2013 and held it in 13 quarters. The position peaked at $1.61M in Q4 2014. 163 funds tracked by Wall St. Rank hold PDLI as of Q2 2018.

Sterling Capital Management reported no remaining PDL BioPharma, Inc. position as of Q2 2018 after selling out during the quarter.
Sterling Capital Management sold 345,406 PDL BioPharma, Inc. shares in Q2 2018, an estimated $1.01M.
Sterling Capital Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 13 quarters.
Sterling Capital Management's PDL BioPharma, Inc. position peaked at $1.61M in Q4 2014.
163 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2018.

Based on Sterling Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.